Plain-English translation of NCT07553338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a small safety study of leronlimab, a medication that has been used safely in other diseases but has never been tested in Alzheimer's disease or mild cognitive impairment before. Researchers want to learn whether this medication is safe for people with memory loss and whether it can reduce inflammation in the brain, which is thought to play a role in Alzheimer's disease.
Current treatments for Alzheimer's only help with symptoms, not the underlying disease. This medication targets brain inflammation, which may be a key part of memory loss—but nobody knows yet if it's safe or effective for this purpose.
You likely qualify if…
You likely don't qualify if…
You would receive the medication once a week for 12 weeks, either at the clinic or at home. Before and after treatment, you would have brain scans (PET and MRI), blood tests, heart monitoring, thinking ability tests, and physical exams. You would also have weekly phone calls with researchers to report any side effects. The entire study lasts about 12 weeks.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States